Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors

NCT03891953 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03891953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 7, 2019
Completion date
October 31, 2026
Enrollment
98 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, melanoma, microsatellite stable colorectal cancer, nasopharyngeal carcinoma, triple negative breast cancer